Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7795081 PK and Safety Study in Overweight/Obese Adults
NCT06982131Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing Arm 1: RO7795081 Sequence with Arm 2: Placebo Sequence (2 arms). Primary endpoints: Incidence and Severity of Adverse Events up to 111 days, Incidence of Abnormal Clinical Laboratory Test Results up to 111 days and 10 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
RO7795081
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06982131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982131.